Published in Eur J Hum Genet on October 24, 2007
Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. BMJ (2009) 2.02
Genetic discrimination and life insurance: a systematic review of the evidence. BMC Med (2013) 1.55
Civilian and military genetics: nondiscrimination policy in a post-GINA world. Am J Hum Genet (2008) 1.24
Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet (2010) 1.05
What's at stake? Genetic information from the perspective of people with epilepsy and their family members. Soc Sci Med (2011) 1.00
In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet (2010) 0.93
Unravelling fears of genetic discrimination: an exploratory study of Dutch HCM families in an era of genetic non-discrimination acts. Eur J Hum Genet (2012) 0.92
Global trends on fears and concerns of genetic discrimination: a systematic literature review. J Hum Genet (2016) 0.83
Factors associated with experiences of genetic discrimination among individuals at risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet (2010) 0.82
Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. Neurology (2015) 0.80
Early Detection of Huntington Disease. Future Neurol (2010) 0.79
Genetics and Personal Insurance: the Perspectives of Canadian Cancer Genetic Counselors. J Genet Couns (2015) 0.77
A polymorphic DNA marker genetically linked to Huntington's disease. Nature (1984) 16.71
Discrimination as a consequence of genetic testing. Am J Hum Genet (1992) 10.40
Genetic discrimination in life insurance: empirical evidence from a cross sectional survey of genetic support groups in the United Kingdom. BMJ (1998) 3.14
Individual, family, and societal dimensions of genetic discrimination: a case study analysis. Sci Eng Ethics (1996) 2.25
Genetic discrimination: perspectives of consumers. Science (1996) 2.13
Cancer risk elicitation and communication: lessons from the psychology of risk perception. CA Cancer J Clin (2007) 1.90
Self-selection in predictive testing for Huntington's disease. Am J Med Genet (1994) 1.84
Attitudes of persons at risk for Huntington disease toward predictive testing. Am J Med Genet (1987) 1.77
Attitudes toward presymptomatic testing in Huntington disease. Am J Med Genet (1987) 1.75
Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. Clin Genet (2003) 1.58
Concerns in a primary care population about genetic discrimination by insurers. Genet Med (2005) 1.48
Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. Am J Med Genet (1989) 1.46
Reluctance to undergo predictive testing: the case of Huntington disease. Am J Med Genet (1993) 1.42
Perceptions of genetic discrimination among at-risk relatives of colorectal cancer patients. Genet Med (2004) 1.39
Selective justice, genetic discrimination, and insurance: should we single out genes in our laws? McGill Law J (2000) 1.34
Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination. Am J Med Genet A (2003) 1.33
What is genetic discrimination, and when and how can it be prevented? Genet Med (2001) 1.27
Impact of genetic testing for Huntington disease on the family system. Am J Med Genet (2000) 1.26
Paradox of a better test for Huntington's disease. J Neurol Neurosurg Psychiatry (2000) 1.23
Genetic testing and Huntington's disease: issues of employment. Lancet Neurol (2004) 1.11
Personal theories of inheritance, coping strategies, risk perception and engagement in hereditary non-polyposis colon cancer families offered genetic testing. Clin Genet (2003) 1.10
Genetic discrimination and screening for hemochromatosis. J Public Health Policy (1994) 1.07
Criteria for concept evaluation. J Adv Nurs (1996) 0.97
Managing genetic discrimination: strategies used by individuals found to have the Huntington disease mutation. Clin Genet (2007) 0.97
Predictive genetic test decisions for Huntington's disease: elucidating the test/no-test dichotomy. J Health Psychol (2005) 0.92
Teacher was refused job because relatives have Huntington's disease. BMJ (2003) 0.92
Genetic discrimination: too few data. Eur J Hum Genet (2003) 0.91
An investigation of genetic counselors' discussion of genetic discrimination with cancer risk patients. J Genet Couns (2003) 0.88
Predictive genetic testing and beyond: a theory of engagement. J Health Psychol (2002) 0.86
Exploring the concept of genetic discrimination. J Bioeth Inq (2005) 0.84
Genetic privacy laws and patients' fear of discrimination by health insurers: the view from genetic counselors. J Law Med Ethics (2000) 0.83
Predictive testing for Huntington's disease using linked DNA markers. N Engl J Med (1988) 0.82
Investigating genetic discrimination in Australia: opportunities and challenges in the early stages. New Genet Soc (2004) 0.79
Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet (2003) 5.82
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet (2003) 4.76
Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell (2006) 4.53
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci (2002) 4.15
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet (2003) 4.07
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet (2009) 3.83
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med (2007) 3.53
Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol (2010) 3.47
Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest (2005) 3.25
Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron (2003) 3.25
Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron (2002) 3.15
Huntingtin-interacting protein HIP14 is a palmitoyl transferase involved in palmitoylation and trafficking of multiple neuronal proteins. Neuron (2004) 3.04
Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature (2004) 2.98
Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nat Genet (2002) 2.90
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med (2011) 2.87
Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. J Pediatr (2011) 2.86
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med (2008) 2.78
Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry (2007) 2.71
Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med (2009) 2.66
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol (2006) 2.55
Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest (2006) 2.55
Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet (2007) 2.54
Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat Cell Biol (2002) 2.50
Capacity to provide informed consent for participation in schizophrenia and HIV research. Am J Psychiatry (2002) 2.41
Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet (2002) 2.39
Accurate prediction of the functional significance of single nucleotide polymorphisms and mutations in the ABCA1 gene. PLoS Genet (2005) 2.38
Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arterioscler Thromb Vasc Biol (2005) 2.36
Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron (2010) 2.36
Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res (2002) 2.28
Mutant DNA-binding domain of HSF4 is associated with autosomal dominant lamellar and Marner cataract. Nat Genet (2002) 2.21
Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. Annu Rev Nutr (2006) 2.20
Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nat Neurosci (2006) 2.19
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol (2009) 2.16
Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A (2005) 2.15
Neurocognitive signs in prodromal Huntington disease. Neuropsychology (2011) 2.14
Increased ABCA1 activity protects against atherosclerosis. J Clin Invest (2002) 2.13
Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol (2008) 2.10
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet (2011) 2.05
The value of positron emission tomography in the clinical evaluation of dementia. J Am Geriatr Soc (2003) 2.05
Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci (2002) 2.05
Brain structure in preclinical Huntington's disease. Biol Psychiatry (2005) 2.05
ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest (2002) 2.03
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. BMJ (2009) 2.02
Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol (2006) 2.00
Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. Can J Neurol Sci (2004) 1.95
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol (2006) 1.94
Spontaneous atherosclerosis in aged lipoprotein lipase-deficient mice with severe hypertriglyceridemia on a normal chow diet. Circ Res (2007) 1.94
Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A (2005) 1.87
When good drugs go bad. Nature (2007) 1.85
A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J Hum Genet (2003) 1.85
Coercion and informed consent in research involving prisoners. Compr Psychiatry (2003) 1.84
Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci (2005) 1.82
Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem (2004) 1.82
Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem (2004) 1.82
Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol Ther (2011) 1.82
HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Mol Genet (2002) 1.79
CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet (2009) 1.78
Practice effects in the prediction of long-term cognitive outcome in three patient samples: a novel prognostic index. Arch Clin Neuropsychol (2006) 1.77
"Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci (2010) 1.76
The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem (2005) 1.74
Medicine. Whole-genome sequencing: the new standard of care? Science (2012) 1.73
Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord (2009) 1.73
Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun (2004) 1.72
Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord (2008) 1.70
Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Hum Mol Genet (2008) 1.70
Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. Am J Hum Genet (2004) 1.70
An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. Mov Disord (2011) 1.68
Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. J Lipid Res (2009) 1.67
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain (2007) 1.66
Short-term practice effects in amnestic mild cognitive impairment: implications for diagnosis and treatment. Int Psychogeriatr (2008) 1.64
More codeine fatalities after tonsillectomy in North American children. Pediatrics (2012) 1.63
Case studies of power and control related to tobacco use during pregnancy. Womens Health Issues (2007) 1.63
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol (2011) 1.62
A functional ABCA1 gene variant is associated with low HDL-cholesterol levels and shows evidence of positive selection in Native Americans. Hum Mol Genet (2010) 1.60
Tetrabenazine. Nat Rev Drug Discov (2009) 1.60
Measures of growth in children at risk for Huntington disease. Neurology (2012) 1.59
A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol (2004) 1.58
Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J Neurosci (2010) 1.58
Neuronal palmitoyl acyl transferases exhibit distinct substrate specificity. FASEB J (2009) 1.55
Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia (2007) 1.54